169 related articles for article (PubMed ID: 19700401)
1. Effects of stability on the biological function of p53.
Khoo KH; Mayer S; Fersht AR
J Biol Chem; 2009 Nov; 284(45):30974-80. PubMed ID: 19700401
[TBL] [Abstract][Full Text] [Related]
2. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
4. Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core.
Khoo KH; Joerger AC; Freund SM; Fersht AR
Protein Eng Des Sel; 2009 Jul; 22(7):421-30. PubMed ID: 19515728
[TBL] [Abstract][Full Text] [Related]
5. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules.
Friedler A; Veprintsev DB; Hansson LO; Fersht AR
J Biol Chem; 2003 Jun; 278(26):24108-12. PubMed ID: 12700230
[TBL] [Abstract][Full Text] [Related]
6. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
Stommel JM; Wahl GM
Cell Cycle; 2005 Mar; 4(3):411-7. PubMed ID: 15684615
[TBL] [Abstract][Full Text] [Related]
7. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
Joerger AC; Allen MD; Fersht AR
J Biol Chem; 2004 Jan; 279(2):1291-6. PubMed ID: 14534297
[TBL] [Abstract][Full Text] [Related]
9. Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro.
Mayer S; Rüdiger S; Ang HC; Joerger AC; Fersht AR
J Mol Biol; 2007 Sep; 372(1):268-76. PubMed ID: 17631895
[TBL] [Abstract][Full Text] [Related]
10. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
11. A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53.
Bechill J; Zhong R; Zhang C; Solomaha E; Spiotto MT
PLoS One; 2016; 11(4):e0154125. PubMed ID: 27124407
[TBL] [Abstract][Full Text] [Related]
12. A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53.
Fraser JA; Madhumalar A; Blackburn E; Bramham J; Walkinshaw MD; Verma C; Hupp TR
J Biol Chem; 2010 Nov; 285(48):37773-86. PubMed ID: 20847049
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
14. Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity.
Lang V; Pallara C; Zabala A; Lobato-Gil S; Lopitz-Otsoa F; Farrás R; Hjerpe R; Torres-Ramos M; Zabaleta L; Blattner C; Hay RT; Barrio R; Carracedo A; Fernandez-Recio J; Rodríguez MS; Aillet F
Mol Oncol; 2014 Jul; 8(5):1026-42. PubMed ID: 24816189
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R; Nomura T; Anderson CW; Sakaguchi K
J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
17. A split-ubiquitin-based assay detects the influence of mutations on the conformational stability of the p53 DNA binding domain in vivo.
Johnsson N
FEBS Lett; 2002 Nov; 531(2):259-64. PubMed ID: 12417323
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamic stability of wild-type and mutant p53 core domain.
Bullock AN; Henckel J; DeDecker BS; Johnson CM; Nikolova PV; Proctor MR; Lane DP; Fersht AR
Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14338-42. PubMed ID: 9405613
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
20. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
Leiter LM; Chen J; Marathe T; Tanaka M; Dutta A
Oncogene; 1996 Jun; 12(12):2661-8. PubMed ID: 8700525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
